Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246623 · ClinicalTrials.gov registry record · Phase 3
US Inhaled Insulin Dose Titration Study
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00246623 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 120 participants.
The verdict
NCT00246623, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American Diabetes Association (ADA). Target goals should be achieved by adjusting the Exubera dose either weekly or twice weekly. Patients will also receive nutritional counseling and diabetes education as part of the study.
Interventions
- PROCEDURE Pulmonary Function Testing
- DRUG Exubera (inhaled insulin)
- PROCEDURE 8-point glucose diary (to assess pre- and post prandial glucoses)
- PROCEDURE Meal Tolerance Test
- PROCEDURE 24-hour continuous glucose monitoring (at select sites)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246623
The ClinicalTrials.gov registry entry for NCT00246623 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pulmonary Function Testing is the first listed.
NCT00246623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246623 about?
NCT00246623 is a clinical study titled "US Inhaled Insulin Dose Titration Study". This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American...
What is the current status of trial NCT00246623?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2005-11. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00246623?
The interventions under investigation include: Pulmonary Function Testing (PROCEDURE), Exubera (inhaled insulin) (DRUG), 8-point glucose diary (to assess pre- and post prandial glucoses) (PROCEDURE), Meal Tolerance Test (PROCEDURE), 24-hour continuous glucose monitoring (at select sites) (PROCEDURE).
Who is sponsoring clinical trial NCT00246623?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.